Statins are known to lower levels of LDL cholesterol, protect against cardiovascular disease, and slightly increase the risk of type 2 diabetes. This analysis of genetic variants in 112,772 participants from 14 studies suggests that PCSK9 inhibitors may do the same. Monoclonal antibodies and other therapies that inhibit proprotein convertase subtilisin–kexin type 9 (PCSK9) have been shown to reduce low-density lipoprotein (LDL) cholesterol levels by approximately 50 to 60% in several randomized trials. 1 – 8 Whether lowering LDL cholesterol levels by inhibiting PCSK9 will reduce the risk of cardiovascular events and, like statins, also increase the risk of new-onset diabetes is unknown. 9 Exploratory and post hoc analyses of randomized trials have suggested that lowering LDL cholesterol levels by approximately 70 mg per deciliter (1.81 mmol per liter) with a PCSK9 inhibitor may reduce the risk of major cardiovascular events by up to . . .